
Moderna Legal Chief Klinger to Retire in 2027
Moderna's chief legal officer Shannon Thyme Klinger plans to step down March 31, 2027, according to a securities filing.
Across Cambridge, coverage here takes in drug development, gene editing, clinical trial results and genomic research. Reporting follows the intersection of biology and technology throughout the city.

Moderna's chief legal officer Shannon Thyme Klinger plans to step down March 31, 2027, according to a securities filing.
November 4, 2026
bit.bio Raises $25 Million in Series DThe Cambridge human cell programming company secured the funding as demand for its human cell models reached record levels.
November 3, 2026
Anthropic Buys Single-Employee Biotech StartupThe July acquisition of Mithril Medicine, a company run by one person using Claude, was disclosed in late October ahead of Anthropic's IPO.
October 21, 2026
Arbor Biotechnologies Names Three New ALS Gene CandidatesThe Cambridge-based company targets ALS-related biological markers using a new proprietary gene editing delivery system.
October 20, 2026
Wave Life Sciences to Host Financial Webcast October 27The Cambridge-based biotechnology firm will discuss its third quarter 2026 financial results during a live conference call.
October 20, 2026
Consortium for Top-Down Proteomics Becomes Proteoform AllianceThe 501(c)(3) non-profit is expanding its mission to advance proteoform biology research and technology.
October 12, 2026
City Therapeutics Raised $100 Million for RNAi TechThe Cambridge-based biotech firm secured new funding to advance its pipeline toward clinical development.
October 7, 2026
Atavistik Bio Will Present HHT Drug ResearchThe company will debut new data on its ATV-1601 therapy for hereditary hemorrhagic telangiectasia this October.
October 6, 2026
Oak Hill Bio Named Joerg Hipp as Science ChiefThe Cambridge-based biotech company appointed a new executive to oversee clinical development of its drug pipeline.
October 5, 2026
AstraZeneca Opened New Cambridge Research CenterThe pharmaceutical giant invested over $1 billion into a new 18-story facility in Kendall Square.
October 1, 2026
Montai Therapeutics Initiated Phase 1 TrialThe Cambridge-based company has begun human testing for its ulcerative colitis drug candidate, MTAI-1025.
Coverage takes in pharmaceutical pipeline updates, public stock offerings, regulatory milestones and the acquisition of research firms. It reaches across the city and the communities around it. The concentration of laboratory space and research facilities creates a distinct pattern of cluster-based development. Commercialization of new therapies remains the primary driver for most stories, often tied to the transition from academic study to clinical application.